Evogene Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Evogene wird ein jährliches Gewinn- und Umsatzwachstum von 37.4% bzw. 45% prognostiziert.

Wichtige Informationen

37.4%

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	49.3%
Wachstumsrate der Einnahmen	45.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

TASE:EVGN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	29	-16	N/A	N/A	2
12/31/2025	17	-20	N/A	N/A	2
12/31/2024	10	-22	N/A	N/A	1
9/30/2024	7	-24	-21	-20	N/A
6/30/2024	9	-20	-20	-20	N/A
3/31/2024	9	-21	-20	-19	N/A
12/31/2023	6	-24	-22	-22	N/A
9/30/2023	6	-20	-19	-18	N/A
6/30/2023	2	-23	-22	-21	N/A
3/31/2023	2	-25	-23	-22	N/A
12/31/2022	2	-27	-25	-24	N/A
9/30/2022	1	-31	-31	-30	N/A
6/30/2022	1	-32	-29	-28	N/A
3/31/2022	1	-29	-29	-28	N/A
12/31/2021	1	-28	-26	-25	N/A
9/30/2021	1	-29	-24	-24	N/A
6/30/2021	1	-26	-23	-22	N/A
3/31/2021	1	-24	-19	-19	N/A
12/31/2020	1	-23	-20	-20	N/A
9/30/2020	1	-21	-18	-17	N/A
6/30/2020	1	-21	-18	-17	N/A
3/31/2020	0	-21	-19	-18	N/A
12/31/2019	1	-18	-19	-18	N/A
9/30/2019	1	-18	-16	-16	N/A
6/30/2019	2	-18	-16	-16	N/A
3/31/2019	2	-19	-16	-16	N/A
12/31/2018	2	-21	-16	-15	N/A
9/30/2018	2	-21	-16	-16	N/A
6/30/2018	2	-21	N/A	-15	N/A
3/31/2018	3	-21	N/A	-16	N/A
12/31/2017	3	-21	N/A	-16	N/A
9/30/2017	4	-21	N/A	-17	N/A
6/30/2017	5	-21	N/A	-16	N/A
3/31/2017	5	-21	N/A	-15	N/A
12/31/2016	7	-20	N/A	-12	N/A
9/30/2016	8	-18	N/A	-12	N/A
6/30/2016	9	-17	N/A	-11	N/A
3/31/2016	10	-17	N/A	-12	N/A
12/31/2015	11	-17	N/A	-12	N/A
9/30/2015	12	-17	N/A	-10	N/A
6/30/2015	12	-17	N/A	-9	N/A
3/31/2015	13	-16	N/A	-8	N/A
12/31/2014	15	-15	N/A	-9	N/A
9/30/2014	17	-14	N/A	-8	N/A
6/30/2014	18	-12	N/A	-7	N/A
3/31/2014	18	-11	N/A	-6	N/A
12/31/2013	15	-9	N/A	-5	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: EVGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: EVGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: EVGN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: EVGNDie Einnahmen des Unternehmens (45% pro Jahr) werden voraussichtlich schneller wachsen als der Markt IL (1.9% pro Jahr).

Hohe Wachstumseinnahmen: EVGNDie Einnahmen des Unternehmens (45% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EVGN in 3 Jahren voraussichtlich hoch sein wird

Evogene Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Evogene Ltd. to Report Q3, 2024 Results on Nov 21, 2024

Evogene Ltd. Announces Executive Changes

Evogene Ltd. to Report Q2, 2024 Results on Aug 22, 2024

Evogene Ltd. to Report Q1, 2024 Results on May 23, 2024

Evogene Ltd., Annual General Meeting, Jun 06, 2024

Evogene Ltd. has filed a Follow-on Equity Offering in the amount of $7.3 million.

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Full year 2023 earnings released: US$0.52 loss per share (vs US$0.65 loss in FY 2022)

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Evogene Ltd. to Report Q4, 2023 Results on Mar 07, 2024

Casterra Ag Ltd., a subsidiary of Evogene Ltd Announces Executive Changes, Effective January 1, 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$0.081 loss per share (vs US$0.16 loss in 3Q 2022)

Evogene Ltd. to Report Q3, 2023 Results on Nov 15, 2023

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Second quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 2Q 2022)

Evogene Ltd. to Report Q2, 2023 Results on Aug 17, 2023

Evogene Ltd 's ChemPass AI Tech-Engine is Introduces with New Breakthrough Machine Learning Technology for Target-Protein Discovery

Biomica Ltd. Reports Interim Positive Results from Pre-Clinical Studies in its IBS Program

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

New minor risk - Share price stability

Evogene Ltd., Annual General Meeting, May 11, 2023

Evogene Ltd. to Report Q1, 2023 Results on May 18, 2023

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Full year 2022 earnings released: US$0.65 loss per share (vs US$0.69 loss in FY 2021)

Third quarter 2022 earnings released: US$0.16 loss per share (vs US$0.19 loss in 3Q 2021)

Evogene Ltd. to Report Q3, 2022 Results on Nov 17, 2022

Here's Why We're Watching Evogene's (TLV:EVGN) Cash Burn Situation

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.15 loss in 2Q 2021)

Evogene Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Evogene Ltd., Annual General Meeting, Sep 08, 2022

Evogene Ltd. to Report Q2, 2022 Results on Aug 31, 2022

We're Keeping An Eye On Evogene's (TLV:EVGN) Cash Burn Rate

Eyal Ronen Joins as Executive Vice President of Business Development of Evogene Ltd., Effective as of June 12, 2022

First quarter 2022 earnings released: US$0.20 loss per share (vs US$0.17 loss in 1Q 2021)

Evogene Ltd. to Report Q1, 2022 Results on May 26, 2022

High number of new directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Will Evogene (TLV:EVGN) Spend Its Cash Wisely?

Evogene Ltd. to Report Q4, 2021 Results on Mar 10, 2022

High number of new directors

Evogene Ltd. Announces Executive Changes

Chief Executive Officer of AgPlenus Ltd. Douglas Eisner has left the company

Third quarter 2021 earnings released: US$0.19 loss per share (vs US$0.18 loss in 3Q 2020)

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.17 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.24 loss in 1Q 2020)

Here's Why We're Not Too Worried About Evogene's (TLV:EVGN) Cash Burn Situation

Full year 2020 earnings released: US$0.83 loss per share (vs US$0.70 loss in FY 2019)

Evogene Ltd. to Report Q4, 2020 Results on Mar 03, 2021

New 90-day high: ₪25.00

Companies Like Evogene (TLV:EVGN) Are In A Position To Invest In Growth

New 90-day high: ₪19.10

New 90-day high: ₪14.94

What Can We Make Of Evogene's (TLV:EVGN) CEO Compensation?

Third quarter 2020 earnings released: US$0.18 loss per share

Evogene Ltd. to Report Q3, 2020 Results on Nov 18, 2020

First half earnings released

New 90-day high - ₪9.46

New 90-day high - ₪5.63

New 90-day high - ₪4.17

First half earnings released

Evogene Ltd. to Report Q2, 2020 Results on Aug 05, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken